How profitable is TG Therapeutics Inc. (TGTX)?

In FY 2025 (10-K), TGTX converted $616.3M of revenue into a 83.7% gross margin, 20% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / TGTX / financials

PTGX (65) MDGL (38) CORT (63) CYTK (28) ⌘ Pro Terminal →

TG Therapeutics Inc. (TGTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$59.95 -2.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.62

TG Therapeutics Inc. (TGTX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $9.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TGTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, TG Therapeutics Inc. (NASDAQ: TGTX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $59.95 (-2.01% 1D, market cap $9.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TGTX ranks #135 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TGTX compare to PTGX and MDGL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TGTX carries a Roarable C (63/100 RQD), trailing P/E of 19.9x, gross margin of 83.7%, and ROIC of 12.0%. By comparison, PTGX (Protagonist Therapeutics Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TGTX?

▼

Per TGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001001316), TG Therapeutics Inc. generated $616.3M in revenue (+87.3% YoY), $447.2M in net income, and -$25.0M in free cash flow against $1.06B in total assets and $245.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $59.62 (-0.55%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

Quant Analyst Panel Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C- · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TGTX)Realized 20D OHLCV Swing Band: ±8.4%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY TGTX SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (29% of score)

20D Institutional Volume Accumulation (±8.4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 12.92 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$54.37-2.2% Next Q

Q2 (-2Q)

Grade C$53.20+7.9% Next Q

Q3 (-1Q)

Grade C$57.40+4.4% Next Q

Current

Grade C$59.95+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TGTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, TGTX faces multiple-compression risk if 19.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.80% YoY Shares) — any gross margin slip below 81.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.56) or 200D SMA ($44.23) invalidates the momentum regime and cuts Target Base ($61.30) toward Bear Floor ($47.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TGTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $233.7M

FY24

Rev $329.0M

FY25

Rev $616.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$616.3M	83.7%	20%	$447.2M	-$25.0M	12%
FY 2024	$329.0M	88.3%	12.7%	$23.4M	-$40.6M	11.5%
FY 2023	$233.7M	83.7%	8.8%	$12.7M	-$41.9M	0.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TGTX)

✓Walkthrough of TGTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.88%⚡ TESTING RESISTANCE

2026-11-03O $58.08H $61.18L $58.08C $59.95VOL 2.86M

RES: $62.01SUP: $52.74SMA50: $55.56SMA200: $44.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TGTX Butterfly Map → + Track TGTX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

13.4%/yr Implied 5Y Growth

vs. +87.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TGTX)

Health Care Rank #135 of 1015 ⚔️ PTGX vs TGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TGTX vs. PTGX, MDGL, CORT, CYTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TG Therapeutics Inc. (TGTX) ranks #135 by composite RQD confidence (63/100, grade C) and #118 by equity capitalization ($9.36B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TGTX at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TGTX ACTIVE TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	-2.01%	$9.36B	Benchmark Subject
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	-3.78%	$9.37B	/ptgx-vs-tgtx →
MDGL Madrigal Pharmaceuticals Inc.	D-	38/100	—	—	-29.7%	+0.19%	$9.94B	/mdgl-vs-tgtx →
CORT Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-0.81%	$8.77B	/cort-vs-tgtx →
CYTK Cytokinetics Incorporated	E	28/100	—	—	-35.0%	-1.52%	$8.76B	/cytk-vs-tgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001001316 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TG Therapeutics Inc. (TGTX) reported GAAP revenue of $616.3M (+87.3% vs. FY2024 revenue of $329.0M , and +163.8% cumulative change since FY2023) , GAAP net income of $447.2M, operating cash flow of -$24.8M, and free cash flow of -$25.0M (+38.4% YoY). On the balance sheet, TGTX closed FY2025 with $1.06B in total assets against $245.6M in total debt (Altman Z-Score: 12.92, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$616.3M	$447.2M	-$24.8M	-$25.0M	$1.06B	$245.6M
FY2024 (FY)	2024-12-31	$329.0M	$23.4M	-$40.5M	-$40.6M	$577.7M	$244.4M
FY2023 (FY)	2023-12-31	$233.7M	$12.7M	-$31.4M	-$41.9M	$4.89B	$1.14B

3. TGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TGTX compare to PTGX and MDGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TGTX?

Where is TGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

TGTX last traded at $59.95 (-2.01% on volume of 2,576,446 shares), positioning the stock +7.90% above its 50-day simple moving average ($55.56) and +35.54% above its 200-day simple moving average ($44.23). Across its 52-week range of $26.76 to $61.76, TGTX sits at the 94.8% percentile with a 14-day RSI of 64.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.4% ($54.91 to $64.99).

Direct Sub-Reports: TGTX RQD Cockpit TGTX 12M Forecast TGTX Earnings & Move TGTX Dividends & DRIP TGTX Insiders & 13F TGTX Whale Options TGTX Profit Sankey TGTX News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

TGTX — TG Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TG Therapeutics Inc. (TGTX) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $59.95 (-2.01% 1D, market capitalization $9.36B).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 12.0%, gross margin of 83.7%, operating margin of 20.0%, and free cash flow yield of -0.28%.
Whale 13F & Options Flow (18/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 0.87x equity beta, Altman Z-Score of 12.92, Piotroski F-Score of 6/9, and Debt/Equity of 0.38x.

2. Business Model, Unit Margins & SEC Financial Trajectory

TG Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile identifies a market capitalization of $8.9B. Recent news items reference multiple sclerosis clinical data presented at MSToronto2026, per the Recent Catalysts section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TG Therapeutics Inc. (TGTX) reported $616.3M in annual revenue (up from $329.0M in FY2024, +87.3% YoY) and $447.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($233.7M revenue, $12.7M net income) through FY2025, TGTX scaled operating cash flow to -$24.8M and free cash flow to -$25.0M, backed by $1.06B in total assets against $245.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 63/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $26.76 – $61.76 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 19.9x trailing P/E and 73.3x EV/EBITDA against 20.0% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TGTX carries a macro regime beta of 0.87 and gross margin of 83.7%.

Key Question #1: Can TGTX sustain or expand its 20.0% operating margin and 12.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $616.3M and free cash flow of -$25.0M, how will capital allocation balance growth reinvestment against $245.6M in total debt?
Key Question #3: How sensitive is TGTX's 16.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

TGTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TG Therapeutics Inc. (TGTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TGTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow

Yahoo Finance report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TG Therapeutics • 1d ago

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

TG Therapeutics report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech

ChartMill report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

TG Therapeutics Stock Climbs 15% On A 6-Day Winning Streak

Trefis report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TradingView report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story

Yahoo Finance report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 2d ago

TG Therapeutics (NASDAQ:TGTX) Pairs Strong Growth With a High-Quality Breakout Setup

ChartMill report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Funds from operations of TG Therapeutics, Inc. – NASDAQ:TGTX

TradingView report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TGTX Bull vs. Bear Conversation Board — What's Your Call at $59.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TGTX 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $76.47 (+25.0%)

📌 Pinned Debate

Institutional accumulation scores 17 of 20 in the RQD rating, and the Altman Z-Score of 12.92 signals strong balance sheet forensics.

Don't sleep on TGTX's setup in Health Care. Institutional accumulation scores 17 of 20 in the RQD rating, and the Altman Z-Score of 12.92 signals strong balance sheet forensics.. Beta of 0.87 means it moves fast when momentum turns, and the 5-pillar RQD gauge (63/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on 19.9x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (83.7%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $49.56 (-19.0%)

Spot @ $61.18

Free cash flow was negative in all three reported periods and the FCF yield is -0.28%, while EV/EBITDA sits at 73.3.

Here is the bear case nobody on the bull side wants to address on TGTX: Free cash flow was negative in all three reported periods and the FCF yield is -0.28%, while EV/EBITDA sits at 73.3.. At 19.9x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.